These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 7537501

  • 1. Inhibition of anti-V3 domain antibody binding to human immunodeficiency virus type-1-infected cells by sulfated polysaccharides.
    Okada T, Patterson BK, Gurney ME.
    Biochem Biophys Res Commun; 1995 Apr 26; 209(3):850-8. PubMed ID: 7537501
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Single basic amino acid substitutions at position 302 or 320 in the V3 domain of HIV type 1 are not sufficient to alter the antiviral activity of dextran sulfate and heparin.
    Okada T, Gurney ME.
    AIDS Res Hum Retroviruses; 1995 May 26; 11(5):571-5. PubMed ID: 7576913
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides.
    Batinić D, Robey FA.
    J Biol Chem; 1992 Apr 05; 267(10):6664-71. PubMed ID: 1551875
    [Abstract] [Full Text] [Related]

  • 6. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding.
    Harrop HA, Coombe DR, Rider CC.
    AIDS; 1994 Feb 05; 8(2):183-92. PubMed ID: 8043225
    [Abstract] [Full Text] [Related]

  • 7. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
    Laman JD, Schellekens MM, Lewis GK, Moore JP, Matthews TJ, Langedijk JP, Meloen RH, Boersma WJ, Claassen E.
    AIDS Res Hum Retroviruses; 1993 Jul 05; 9(7):605-12. PubMed ID: 8369165
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HIV type 1 infection of CD4+ T cells depends critically on basic amino acid residues in the V3 domain of envelope glycoprotein 120.
    Okada T, Patterson BK, Otto PA, Gurney ME.
    AIDS Res Hum Retroviruses; 1994 Jul 05; 10(7):803-11. PubMed ID: 7986586
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K, Durani V, Miranda ER, Citron M, Liang X, Schleif W, Joyce JG, Varadarajan R.
    Biochem J; 2006 Nov 01; 399(3):483-91. PubMed ID: 16827663
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120.
    Stein CA, Cleary AM, Yakubov L, Lederman S.
    Antisense Res Dev; 1993 Nov 01; 3(1):19-31. PubMed ID: 8495104
    [Abstract] [Full Text] [Related]

  • 14. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
    Platt EJ, Kuhmann SE, Rose PP, Kabat D.
    J Virol; 2001 Dec 01; 75(24):12266-78. PubMed ID: 11711617
    [Abstract] [Full Text] [Related]

  • 15. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 16. Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients.
    Silvestris F, Nagata S, Cafforio P, Silvestris N, Dammacco F.
    J Exp Med; 1996 Dec 01; 184(6):2287-300. PubMed ID: 8976184
    [Abstract] [Full Text] [Related]

  • 17. CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments.
    Meshcheryakova D, Andreev S, Tarasova S, Sidorova M, Vafina M, Kornilaeva G, Karamov E, Khaitov R.
    Mol Immunol; 1993 Aug 01; 30(11):993-1001. PubMed ID: 8102473
    [Abstract] [Full Text] [Related]

  • 18. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.
    J Pept Sci; 1995 Aug 01; 1(2):109-23. PubMed ID: 9222988
    [Abstract] [Full Text] [Related]

  • 19. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S.
    J Virol; 2007 Apr 01; 81(8):3757-68. PubMed ID: 17251298
    [Abstract] [Full Text] [Related]

  • 20. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR, Strick N, Debnath AK.
    J Mol Recognit; 1995 Apr 01; 8(6):345-57. PubMed ID: 9052975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.